PURPOSE: Metabolic response to treatment measured by fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET has prognostic implications in many cancers. This study investigated the association between survival and early changes on (18)F-FDG PET/computed tomography (CT) for patients with BRAF-mutant melanoma receiving combined BRAF and MEK inhibition therapy. MATERIALS AND METHODS: Overall, 24 patients with advanced BRAF-mutant melanoma were included. Patients were treated with a BRAF inhibitor (vemurafenib or dabrafenib) and a MEK inhibitor (cobimetinib or trametinib), and were imaged at baseline and shortly thereafter with (18)F-FDG PET/CT. Each scan yielded two values of maximum standardized uptake value (SUVmax): one for the most metabolically active focus and one for the least responsive focus. Short-term treatment response was assessed by evaluating the target lesions using the EROTC criteria. A Cox proportional hazards model was used to examine associations between overall survival (OS) and progression-free survival (PFS) and changes in SUVmax. RESULTS: The mean time to follow-up (18)F-FDG PET/CT was 26 days. At follow-up, two patients achieved a complete response. For the most metabolically active focus, 22 patients showed a partial response. For the least responsive focus, 18 patients showed a partial response, two had stable disease, and two had progressive disease.A total of 16 patients were alive at the end of the study. For the most metabolically active tumor, no association was observed between changes in SUVmax and OS (P=0.73) or PFS (P=0.17). For the least responsive tumor, change in SUVmax was associated with PFS [hazard ratio (HR)=1.34, 95% confidence interval (CI): 1.06-1.71, P=0.01], but not OS (P=0.52). The ECOG score was associated with OS (HR=11.81, 95% CI: 1.42-97.60, P=0.02) and PFS (HR=24.72, 95% CI: 3.23-189.42, P=0.002). CONCLUSION: Change in SUVmax for the least responsive tumor and baseline functional performance may be useful prognostic indicators for PFS in patients with BRAF-mutant melanoma.
PURPOSE: Metabolic response to treatment measured by fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET has prognostic implications in many cancers. This study investigated the association between survival and early changes on (18)F-FDGPET/computed tomography (CT) for patients with BRAF-mutant melanoma receiving combined BRAF and MEK inhibition therapy. MATERIALS AND METHODS: Overall, 24 patients with advanced BRAF-mutant melanoma were included. Patients were treated with a BRAF inhibitor (vemurafenib or dabrafenib) and a MEK inhibitor (cobimetinib or trametinib), and were imaged at baseline and shortly thereafter with (18)F-FDGPET/CT. Each scan yielded two values of maximum standardized uptake value (SUVmax): one for the most metabolically active focus and one for the least responsive focus. Short-term treatment response was assessed by evaluating the target lesions using the EROTC criteria. A Cox proportional hazards model was used to examine associations between overall survival (OS) and progression-free survival (PFS) and changes in SUVmax. RESULTS: The mean time to follow-up (18)F-FDGPET/CT was 26 days. At follow-up, two patients achieved a complete response. For the most metabolically active focus, 22 patients showed a partial response. For the least responsive focus, 18 patients showed a partial response, two had stable disease, and two had progressive disease.A total of 16 patients were alive at the end of the study. For the most metabolically active tumor, no association was observed between changes in SUVmax and OS (P=0.73) or PFS (P=0.17). For the least responsive tumor, change in SUVmax was associated with PFS [hazard ratio (HR)=1.34, 95% confidence interval (CI): 1.06-1.71, P=0.01], but not OS (P=0.52). The ECOG score was associated with OS (HR=11.81, 95% CI: 1.42-97.60, P=0.02) and PFS (HR=24.72, 95% CI: 3.23-189.42, P=0.002). CONCLUSION: Change in SUVmax for the least responsive tumor and baseline functional performance may be useful prognostic indicators for PFS in patients with BRAF-mutant melanoma.
Authors: Juliano J Cerci; Luís F Pracchia; Camila C G Linardi; Felipe A Pitella; Dominique Delbeke; Marisa Izaki; Evelinda Trindade; José Soares; Valeria Buccheri; José C Meneghetti Journal: J Nucl Med Date: 2010-08-18 Impact factor: 10.057
Authors: Deniz Kahraman; Matthias Scheffler; Thomas Zander; Lucia Nogova; Adriaan A Lammertsma; Ronald Boellaard; Bernd Neumaier; Roland T Ullrich; Arne Holstein; Markus Dietlein; Jürgen Wolf; Carsten Kobe Journal: J Nucl Med Date: 2011-11-07 Impact factor: 10.057
Authors: John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: V A Passero; B F Branstetter; Y Shuai; D E Heron; M K Gibson; S Y Lai; S W Kim; J R Grandis; R L Ferris; J T Johnson; A Argiris Journal: Ann Oncol Date: 2010-04-29 Impact factor: 32.976
Authors: David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen Journal: Nature Date: 2005-11-06 Impact factor: 49.962
Authors: Grant A McArthur; Igor Puzanov; Ravi Amaravadi; Antoni Ribas; Paul Chapman; Kevin B Kim; Jeffrey A Sosman; Richard J Lee; Keith Nolop; Keith T Flaherty; Jason Callahan; Rodney J Hicks Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544
Authors: H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price Journal: Eur J Cancer Date: 1999-12 Impact factor: 9.162
Authors: Andrea Forschner; Tobias Sinnberg; Gabi Mroz; Christopher Schroeder; Christian Philipp Reinert; Sergios Gatidis; Michael Bitzer; Thomas Eigentler; Claus Garbe; Heike Niessner; Martin Röcken; Cristiana Roggia; Sorin Armeanu-Ebinger; Olaf Riess; Sven Mattern; Dominik Nann; Irina Bonzheim Journal: Front Oncol Date: 2021-03-01 Impact factor: 6.244
Authors: Ashleigh C McEvoy; Lydia Warburton; Zeyad Al-Ogaili; Liesl Celliers; Leslie Calapre; Michelle R Pereira; Muhammad A Khattak; Tarek M Meniawy; Michael Millward; Melanie Ziman; Elin S Gray Journal: BMC Cancer Date: 2018-07-09 Impact factor: 4.430
Authors: Ralf S Eschbach; Philipp M Kazmierczak; Maurice M Heimer; Andrei Todica; Heidrun Hirner-Eppeneder; Moritz J Schneider; Georg Keinrath; Olga Solyanik; Jessica Olivier; Wolfgang G Kunz; Maximilian F Reiser; Peter Bartenstein; Jens Ricke; Clemens C Cyran Journal: Cancer Imaging Date: 2018-01-18 Impact factor: 3.909